載入中
NASDAQHealthcareBiotechnology
最新資料
US$4.77
−US$0.22 · -4.41%
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
前收盤價
US$4.77
−US$0.22 · -4.41%
盤後
US$4.63
−US$0.14 · -2.94%
10月7日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
日內區間
目前US$4.77
52週區間
目前US$4.77
盤中時間採用ET。市場資料可能有所延遲。
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
日內區間
目前US$4.77
52週區間
目前US$4.77
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | — | — | — | 2.6萬 USD |
| 銷貨成本 | — | — | — | 2.16萬 USD |
| 毛利 | — | — | — | 4429 USD |
| 研究與開發 | 298.59萬 USD | — | — | — |
| 銷售、一般及管理費用 | 125.32萬 USD | 29.04萬 USD | 1.93萬 USD | 2.47萬 USD |
| 營業費用 | 423.91萬 USD | 36.51萬 USD | 1.93萬 USD | 2.47萬 USD |
| 利息支出 | 8537 USD | — | — | — |
| 折舊和攤銷 | 7.94萬 USD | — | 1815 USD | 2.12萬 USD |
| 營業利益 | −423.91萬 USD | −36.51萬 USD | −1.93萬 USD | −2.02萬 USD |
| 淨利 | −422.51萬 USD | −36.15萬 USD | −1.92萬 USD | −2.02萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月20日 | 1:20 | — | — |
已生效 2026年8月20日
1:20
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
